What is NDC 61958-2901?

61958-2901 is the product NDC for Veklury (remdesivir), Remdesivir 100 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Gilead Sciences, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Gilead Sciences, Inc., NDC labeler code 61958. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Veklury?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Veklury NDC 61958-2901 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)61958-2901Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61958-2901Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61958-2901-2	6195829010261958290102	1 VIAL, SINGLE-DOSE in 1 CARTON (61958-2901-2) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSEMarketed from Nov 1, 2020

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Veklury
Generic name (nonproprietary): remdesivir
Active ingredients: Remdesivir — 100 mg/1
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Gilead Sciences, Inc.NDC labeler code 61958
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 214787
Marketing start: Nov 1, 2020
Listing expires: Dec 31, 2027
Identifiers: Product ID 61958-2901_24078e66-bb6a-4aa3-a748-30762b6416afSPL ID 24078e66-bb6a-4aa3-a748-30762b6416afSPL set ID c0978fa8-53ff-4ca2-82a7-567fd3e958caRxCUI 2284960, 2367758, 2395502, 2395504UNII 3QKI37EEHE
Pharmacologic class: SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N461958290102 followed by a unit qualifier and the quantity

Package 61958-2901-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 29, 2026.

Indications (excerpt from the label)

VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are [see Clinical Studies (14) ] : Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. VEKLURY is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are: Hospitalized, or Not hospitalized and…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 61958-2901

What is NDC 61958-2901?: 61958-2901 is the product NDC for Veklury (remdesivir), Remdesivir 100 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Gilead Sciences, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Veklury (Remdesivir).
What is the active ingredient?: Remdesivir.
Who is the labeler?: Gilead Sciences, Inc., NDC labeler code 61958. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Veklury?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Veklury (Remdesivir) NDC 61958-2901